Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without
Go back to Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without| FATE THERAPEUTICS (NASDAQ: FATE) | Delayed: 2.06 +0.09 (4.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.97 | 52 Week High | $4.76 | |||
| Open | $2.00 | 52 Week Low | $1.46 | |||
| Day High | $2.16 | P/E | N/A | |||
| Day Low | $1.93 | EPS | $-1.91 | |||
| Volume | 4,698,730 | |||||
